Expertise in
6
conditions

Lucas T. Moreno

Barcelona, CT, ES 
Expertise in
6
conditions
Barcelona, CT, ES 

Overview

Lucas Moreno practices practicing medicine in Barcelona, Spain.

Mr. Moreno is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, Gliomatosis Cerebri, and Rhabdomyosarcoma.

He is actively involved in clinical research, co-authoring 134 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Barcelona, CT, Spain
Other Locations
Nino Jesus, MD, Spain
Bellaterra, CT, Spain
Murcia, MU, Spain
Madrid, MD 28006, Spain
Almagro, MD 28029, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Study Phase: Phase 1
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Irinotecan, Temozolomide
Study Phase: Phase 1/Phase 2
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

134 Total Publications

Establishing a Multicenter Personalized Medicine Program in Childhood, Adolescent, and Young Adult Cancer in Spain: The SEHOP-PENCIL Project.
Establishing a Multicenter Personalized Medicine Program in Childhood, Adolescent, and Young Adult Cancer in Spain: The SEHOP-PENCIL Project.
Journal: JCO precision oncology
Published: September 01, 2026

Frequently Asked Questions about Lucas T. Moreno

Is Lucas T. Moreno a top-rated expert for Embryonal Tumor with Multilayered Rosettes?

MediFind is an objective health platform that identifies experts based on real-world data. Lucas T. Moreno is classified as an Elite expert for Embryonal Tumor with Multilayered Rosettes, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Lucas T. Moreno participate in research or clinical trials?

Yes. Lucas T. Moreno has published 134 articles and abstracts on conditions like Embryonal Tumor with Multilayered Rosettes. You can view a list of Lucas T. Moreno's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Moreno's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile